These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20571489)

  • 1. Quality of methods for assessing and reporting serious adverse events in clinical trials of cancer drugs.
    Belknap SM; Georgopoulos CH; West DP; Yarnold PR; Kelly WN
    Clin Pharmacol Ther; 2010 Aug; 88(2):231-6. PubMed ID: 20571489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there room for improvement in adverse event reporting in the era of targeted therapies?
    Edgerly M; Fojo T
    J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.
    Mahoney MR; Sargent DJ; O'Connell MJ; Goldberg RM; Schaefer P; Buckner JC
    J Clin Oncol; 2005 Dec; 23(36):9275-81. PubMed ID: 16361625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse event reporting in publications compared with sponsor database for cancer clinical trials.
    Scharf O; Colevas AD
    J Clin Oncol; 2006 Aug; 24(24):3933-8. PubMed ID: 16921045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS).
    Benjamin DM; Pendrak RF
    J Clin Pharmacol; 2003 Jul; 43(7):754-9. PubMed ID: 12856390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, comparative methods of detection, and preventability of adverse drug events.
    Al-Tajir GK; Kelly WN
    Ann Pharmacother; 2005; 39(7-8):1169-74. PubMed ID: 15928265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update.
    Lassere MN; Johnson KR; Boers M; Carlton K; Day RO; de Wit M; Edwards IR; Fries JF; Furst DE; Kirwan JR; Tugwell PS; Woodworth TG; Brooks PM
    J Rheumatol; 2005 Oct; 32(10):2037-41. PubMed ID: 16206366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
    Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication safety program reduces adverse drug events in a community hospital.
    Cohen MM; Kimmel NL; Benage MK; Cox MJ; Sanders N; Spence D; Chen J
    Qual Saf Health Care; 2005 Jun; 14(3):169-74. PubMed ID: 15933311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supporting quality and patient safety in cancer clinical trials.
    Badalucco S; Reed KK
    Clin J Oncol Nurs; 2011 Jun; 15(3):263-5. PubMed ID: 21624861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug event reporting in intensive care units: a survey of current practices.
    Kane-Gill SL; Devlin JW
    Ann Pharmacother; 2006; 40(7-8):1267-73. PubMed ID: 16849619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
    Anderson SJ
    J Clin Oncol; 2006 Aug; 24(24):3821-2. PubMed ID: 16921032
    [No Abstract]   [Full Text] [Related]  

  • 15. The state of dietary supplement adverse event reporting in the United States.
    Gardiner P; Sarma DN; Low Dog T; Barrett ML; Chavez ML; Ko R; Mahady GB; Marles RJ; Pellicore LS; Giancaspro GI
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):962-70. PubMed ID: 18613260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
    Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
    J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project.
    Belknap SM; Georgopoulos CH; Lagman J; Weitzman SA; Qualkenbush L; Yarnold PR; Edwards BJ; McKoy JM; Trifilio SM; West DP
    J Clin Pharmacol; 2013 Dec; 53(12):1334-40. PubMed ID: 24030903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project--six sites, United States, January 1-June 15, 2004.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Apr; 54(15):380-3. PubMed ID: 15843786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database.
    Eiden C; Peyrière H; Cociglio M; Djezzar S; Hansel S; Blayac JP; Hillaire-Buys D;
    Ann Pharmacother; 2007 May; 41(5):755-63. PubMed ID: 17456542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES).
    Jhung MA; Budnitz DS; Mendelsohn AB; Weidenbach KN; Nelson TD; Pollock DA
    Med Care; 2007 Oct; 45(10 Supl 2):S96-102. PubMed ID: 17909391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.